BIOXCEL THERAPEUTICS INC. - COMMON STOCK

BioXcel Therapeutics Announces First Patients Dosed in SERENITY III Phase 3 Trial for Acute Treatment of Agitation in Adults with Bipolar I or II Disorder or Schizophrenia

30 Nov 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Two Upcoming Investor Conferences

14 Nov 2022 06:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Third Quarter 2022 Financial Results and Recent Operational Highlights

10 Nov 2022 06:00:04 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Third Quarter 2022 Financial Results on November 10, 2022

27 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Host IGALMI™ Commercial Day on October 18, 2022

05 Oct 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the H.C. Wainwright 24th Annual Global Investment Conference

07 Sep 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Operational Highlights

09 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at the Canaccord Genuity 42nd Annual Growth Conference

03 Aug 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report Second Quarter 2022 Financial Results on August 9, 2022

26 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Appoints Michael P. Miller to Board of Directors

05 Jul 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences

07 Jun 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Updated Presentation Time at H.C. Wainwright Global Investment Conference

20 May 2022 06:00:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports First Quarter 2022 Financial Results and Recent Operational Highlights

09 May 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Present at Three Upcoming Investor Conferences

05 May 2022 06:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients with Alzheimer’s Disease

03 May 2022 06:00:02 By Nasdaq GlobeNewswire

BioXcel Therapeutics to Report First Quarter 2022 Financial Results on May 9, 2022

26 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces Formation of OnkosXcel Therapeutics to Develop Medicines Focused in Oncology

19 Apr 2022 06:05:00 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces $260 Million Strategic Financing with Oaktree and Qatar Investment Authority

19 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Announces FDA Approval of IGALMI™ (dexmedetomidine) Sublingual Film for Acute Treatment of Agitation Associated with Schizophrenia or Bipolar I or II Disorder in Adults

06 Apr 2022 06:00:01 By Nasdaq GlobeNewswire

BioXcel Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights

10 Mar 2022 06:04:55 By Nasdaq GlobeNewswire